Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

12. Mai 2026 aktualisiert von: Valenta Pharm JSC

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

300

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Russland
      • Moscow, Russland, 119571
        • Rekrutierung
        • Unimed-C Jsc
        • Kontakt:
          • Olga Orlova, MD
          • Telefonnummer: +7 (919) 994-90-14
          • E-Mail: orlelik@mail.ru
      • Moscow, Russland, 117556
        • Rekrutierung
        • State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare"
        • Kontakt:
      • Moscow, Russland
        • Rekrutierung
        • The State Budgetary Healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
        • Kontakt:
      • Novosibirsk, Russland
        • Rekrutierung
        • Limited Liability Company "ErSi Medical"
        • Kontakt:
      • Perm, Russland, 614990
        • Rekrutierung
        • Federal State Budgetary Educational Institution of Higher Education "Academician E.A. Wagner Perm State Medical University" of the Ministry of Healthcare of the Russian Federation
        • Kontakt:
      • Saint Petersburg, Russland, 194358
        • Rekrutierung
        • St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117"
        • Kontakt:
      • Saint Petersburg, Russland, 196143
        • Rekrutierung
        • Limited Liability Company "Research Center Eco-Safety"
        • Kontakt:
      • Saint Petersburg, Russland, 196158
        • Rekrutierung
        • Limited Liability Company "Clinic Zvezdnaya"
        • Kontakt:
      • Saratov, Russland, 410071
        • Rekrutierung
        • State Healthcare Institution "Saratov City Clinical Hospital No. 5"
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Males and females aged 18-70 years.
  2. Diagnosed with chronic cholecystitis (K81.1) and/or dyskinesia of the cystic duct or gallbladder (K82.8) prior to enrollment; diagnosis supported by clinical history of exacerbations and remissions and/or imaging/laboratory findings.
  3. Upper abdominal pain or discomfort attributable to gallbladder or biliary tract dysfunction (per investigator assessment), accompanied by ≥1 of the following: heartburn, belching, nausea, abdominal bloating, borborygmi (stomach rumbling), flatulence, constipation, or diarrhea.
  4. Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
  5. Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
  6. The total bilirubin level does not exceed 2 times the upper limit of normal (no more than 42 μmol/L).
  7. Women who are either sexually abstinent or using effective contraception methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
  8. Signed and dated informed consent from.

Non-inclusion Criteria:

  1. Gastric or duodenal ulcer, erosive gastroesophageal reflux disease (GERD), or other inflammatory/erosive gastrointestinal diseases in the acute stage, unless stable remission for ≥ 1 year since the last exacerbation.
  2. Indication for surgical or endoscopic intervention due to exacerbation of chronic cholecystitis or complications of biliary tract dyskinesia.
  3. Toxic megacolon.
  4. Paralytic ileus.
  5. Gilbert's syndrome.
  6. Choledocholithiasis (or a high risk of its development, as determined by the investigator);
  7. Impaired bile outflow due to adhesions in the abdominal cavity.Abdominal adhesion disease.
  8. Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
  9. Gastrointestinal malignancy (including history of) or suspected gastrointestinal malignancy (e.g., blood in stool, unexplained weight loss, fever, anemia).
  10. Any other oncological diseases known at the time of screening, or suspicion thereof.
  11. History of gastrointestinal surgery, including cholecystectomy or endoscopic sphincterotomy (appendectomy excluded).
  12. Use of prohibited therapy medications within 3 days prior to randomization.
  13. History of mental illnesses.
  14. Chronic heart failure IIb-III stages and/or III-IV functional classes according to NYHA, angina pectoris III-IV functional classes.
  15. Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
  16. History of or current hepatic impairment; or liver test abnormalities: AST, ALT, ALP, or GGT >3 above the upper limit of normal (ULN); total bilirubin >2 ULN or clinical jaundice.
  17. HIV, syphilis, viral hepatitis B or C, including in history.
  18. Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
  19. Liver cirrhosis.
  20. Hypersensitivity to the active ingridient or any of the excipients of the drug 4-MUST.
  21. Severe, decompensated, or unstable somatic conditions that are life-threatening, worsen prognosis, or preclude safe study participation.
  22. Diabetes mellitus in a state of subcompensation and decompensation.
  23. Systemic connective tissue diseases.
  24. Autoimmune diseases.
  25. Indication for hemodialysis procedures.
  26. Epilepsy or seizures of unclear etiology, including in history.
  27. Alcoholism, substance abuse or drug addiction, including in history.
  28. Uncorrected electrolyte disturbances.
  29. QTcF interval on a 12-lead electrocardiogram (ECG) ≥430 ms in men and ≥450 ms in women.
  30. Episodes of constipation during the last 3 months that required the prescription of drug therapy.
  31. History of surgery within 6 month prior to screening.
  32. Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
  33. Patients who require prohibited concomitant therapy within this study framework.
  34. Participation in another clinical trial within the last 3 months prior to the screening visit date.
  35. Unwillingness or inability to comply with study procedures and protocol requirements..
  36. Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.

Exclusion Criteria:

  1. Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
  2. Lack of Efficacy. Study treatment will be discontinued if no clinical improvement is observed by Visit 3 (Day 15 ± 1), defined as persistence or worsening of upper abdominal pain/discomfort (assessed by Visual Analog Scale [VAS]) compared to baseline. Upon discontinuation, alternative therapy will be initiated at the investigator's discretion.
  3. Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
  4. Requirement for prohibited concomitant therapy.
  5. Use of Duspatalin® (INN: mebeverine) for more than 3 consecutive days or for more than 5 days in total throughout the study.
  6. If the investigator judges that comtinued participation in the study would harm the patient.
  7. Pregnancy or the need for breastfeeding.
  8. Major protocol deviation by the subject with respect to procedures outlined in the Informed Consent Form (ICF).
  9. Withdrawal of informed consent by the subject (decision to discontinue study participation).
  10. Lost to follow-up: Inability to contact the subject after ≥3 documented attempts via mobile phone, landline (if applicable), and designated emergency contact.
  11. Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
  12. Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: 4-MUST
4-MUST: 384 mg (3 tablets), orally three times a day (TID), 30 min before meals. Total daily dose - 1152 mg.
Arzneimittel: 4-Must
128 mg Trimebutin-4-Methylumbellifer-Sulfat-Tablette.
Andere Namen:
  • Trimebutine 4-methylumbelliferylsulfat
Placebo-Komparator: Placebo
Placebo: 3 tablets, orally three times a day (TID), 30 min before meals.
Arzneimittel: Placebo
Placebo-Tablette.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline
Zeitfenster: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sicherheit und Verträglichkeit: Vitalzeichen - systolischer Blutdruck (SBP)
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
SBP, MMHG
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Sicherheit und Verträglichkeit: Vitalzeichen - Diastolischer Blutdruck (DBP)
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
DBP, MMHG
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Sicherheit und Verträglichkeit: Vitalfunktionen - Atemfrequenz (RR)
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
RR, Atemzusagen pro Minute
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Sicherheit und Verträglichkeit: Vitalzeichen - Herzfrequenz (HR)
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
HR, Schläge pro Minute
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Sicherheit und Verträglichkeit: Vitalfunktionen - Körpertemperatur
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Körpertemperatur, Celsius -Skala
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Körperliche Untersuchungsergebnisse: Herz -Kreislauf -System
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands des kardiovaskulären Systems bei körperlicher Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Ergebnisse der körperlichen Untersuchung: Verdauungstrakt
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands des Verdauungstrakts auf die körperliche Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Ergebnisse der körperlichen Untersuchung: Endokrines System
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands des endokrinen Systems bei der körperlichen Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Körperliche Untersuchungsergebnisse: Muskuloskelettsystem
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands des Bewegungsapparates auf körperliche Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Körperliche Untersuchungsergebnisse: Nervensystem
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands des Nervensystems bei körperlicher Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Ergebnisse der körperlichen Untersuchung: sensorische Systeme
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands der sensorischen Systeme bei der körperlichen Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Ergebnisse der körperlichen Untersuchung: Haut/sichtbare Schleimhautmembranen
Zeitfenster: Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Eine Bewertung des Zustands der Haut/sichtbaren Schleimhäute bei körperlicher Untersuchung (normaler Zustand oder Liste der abnormalen Bedingungen, falls vorhanden)
Screening, Tag 1, Tag 8 ± 1, Tag 15 ± 1, Tag 22 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Hämoglobin
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Hämoglobin (g/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Hämatokrit
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Hämatokrit (%)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Anzahl der roten Blutkörperchen
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Anzahl der roten Blutkörperchen (Zellen/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Thrombozytenzahl
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Thrombozytenzahl (Zellen/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Leukozytenzahl
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenzahl (Zellen/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Erythrozyten -Sedimentationsrate
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Erythrozyten -Sedimentationsrate (mm/h)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Myelozyten
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Myelozyten, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Bandneutrophile
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Bandneutrophile, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - segmentierte Neutrophile
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (segmentierte Neutrophile, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Eosinophile
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Eosinophile, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Basophile
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Basophile, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Monozyten
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Monozyten, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Klinische Blutuntersuchung - Lymphozyten
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Leukozytenformel (Lymphozyten, %)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Glukose
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Glukosekonzentration (mmol/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Blutchemie - Cholesterin
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Gesamtcholesterinkonzentration (mmol/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Protein
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Gesamtproteinkonzentration (g/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Bilirubin
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Gesamtbilirubinkonzentration (Mikromol/L)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Kreatinin
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Kreatininkonzentration (Mikromol/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Alkalische Phosphatase
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Alkalische Phosphataseaktivität (U/L)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Alanin -Transaminase
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Alanin -Transaminase -Aktivität (U/L)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Blutchemie - Aspartattransaminase
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Aspartattransaminaseaktivität (U/L)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Blutchemie - Gamma -GTP
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Gamma-Glutaryltranspeptidase-Aktivität (U/L)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Urinanalyse - Spezifisches Gewicht
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Spezifische Gewicht des Urins
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Urinanalyse - PH
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
pH -Wert des Urins
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Urinanalyse - Protein
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Proteinkonzentration (g/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse der Labor- und Instrumentaluntersuchungen: Urinanalyse - Glukose
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Glukosekonzentration (mmol/l)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Urinanalyse - rote Blutkörperchen
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Roter Blutkörperchengehalt (Anzahl in Sicht)
Screening, Tag 15 ± 1, Tag 29 ± 1
Ergebnisse von Labor- und Instrumentaluntersuchungen: Urinanalyse - Weiße Blutkörperchen
Zeitfenster: Screening, Tag 15 ± 1, Tag 29 ± 1
Weißer Blutkörperchengehalt (Anzahl in Sicht)
Screening, Tag 15 ± 1, Tag 29 ± 1
Mean reduction in the severity of pain/discomfort in the upper abdomen according to VAS by days 2-28 from the start of therapy
Zeitfenster: Day 2 - Day 28
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 2 - Day 28
Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more) by days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more) by days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more)
Zeitfenster: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more)
Zeitfenster: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Frequency of clinical recovery (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less) by days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Time to clinical recovery (reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less)
Zeitfenster: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Change in the total score of gastroenterological symptom severity according to the GSRS questionnaire by days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in dyspeptic symptom severity, as assessed by the GSRS, expressed as score changes from baseline in the Abdominal Pain, Reflux, Indigestion, Diarrhea, and Constipation syndrome subscales at Days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in the severity of individual symptoms of dyspeptic disorders according to the GSRS questionnaire in points by days 8, 15, 22, and 29 following treatment initiation.
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in quality of life according to the total score on the SF-36 questionnaire by day 29 from treatment initiation.
Zeitfenster: Day 29 ± 1
SF-36 (Short Form 36 Health Survey) is a self-reported questionnaire. It consists of 36 items that cover eight health domains: Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Bodily pain, General health perceptions, Vitality (energy and fatigue), Social functioning, Mental health. SF-36 produces a profile of scores for each domain, which can be summarized into two main components: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, where lower scores indicate greater disability and higher scores indicate better health.
Day 29 ± 1
Change in the total score on the PAGI-SYM questionnaire by days 15 and 29 from treatment initiation.
Zeitfenster: Day 15 ± 1, and 29 ± 1
PAGI-SYM (Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index) is a patient-reported questionnaire designed to assess the severity of symptoms in upper gastrointestinal disorders (GERD, dyspepsia, and gastroparesis). It consists of 20 items grouped into six subscales: Heartburn/Regurgitation, Fullness/Early Satiety, Nausea/Vomiting, Bloating, Upper Abdominal Pain, and Lower Abdominal Pain. Each symptom is rated on a 6-point Likert scale from 0 (none) to 5 (very severe). The questionnaire provides a profile of scores for each subscale, as well as a total score. Higher scores indicate greater symptom severity.
Day 15 ± 1, and 29 ± 1
change in the total score on the Visceral Sensitivity Index questionnaire by days 15 and 29 from the start of therapy
Zeitfenster: Day 15 ± 1, and 29 ± 1
VSI (Visceral Sensitivity Index) is a patient-reported questionnaire measuring gastrointestinal-specific anxiety (cognitive, affective, and behavioral responses to GI sensations). It consists of 15 items rated on a 6-point scale, producing a total score from 0 to 75. Higher scores indicate greater GI-specific anxiety. Originally validated in IBS patients, it is now used across various GI disorders.
Day 15 ± 1, and 29 ± 1
Change in the total score on the Emotional Distress - Depression - Short Form 4a questionnaire by days 8, 15, 22, and 29 from the start of therapy
Zeitfenster: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Emotional Distress - Depression - Short Form 4a (PROMIS Depression SF 4a) is a patient-reported questionnaire assessing depression symptoms over the past 7 days. It consists of 4 items rated on a 5-point scale. Raw scores (4-20) are converted to a standardized T-score (mean=50, SD=10). Higher scores indicate greater depression severity.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Safety and Tolerability: adverse event (AE) rate
Zeitfenster: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Frequency of adverse events (AEs) or serious AEs (SAEs)
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: adverse event (AE) number
Zeitfenster: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number of adverse events (AEs) or serious AEs (SAEs)
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: AEs associated with the study drug
Zeitfenster: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number and frequency of AEs associated with the study drug
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: SAEs associated with the study drug
Zeitfenster: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number and frequency of SAEs associated with the study drug
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: treatment discontinuation
Zeitfenster: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Percentage of patients who discontinued treatment due to the occurrence of AEs/SAEs
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Physical examination results: respiratory system
Zeitfenster: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1
Results of laboratory and instrumental examinations: blood chemistry - CRP
Zeitfenster: Screening, day 15 ± 1, day 29 ± 1
C-reactive protein, CRP (mg/L)
Screening, day 15 ± 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
Zeitfenster: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
Zeitfenster: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
Zeitfenster: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval
Zeitfenster: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave) (Frederica correction)
Screening, day 1, day 29 ± 1

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Valenta Pharm JSC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

12. Dezember 2025

Primärer Abschluss (Geschätzt)

31. Dezember 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

12. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Mai 2026

Zuerst gepostet (Tatsächlich)

19. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. Mai 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • GIB-03-04-2025

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Czech Republic

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren